metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Enfermedad pulmonar intersticial
Journal Information
Vol. 121. Issue 11.
Pages 426-430 (January 2003)
Share
Share
Download PDF
More article options
Vol. 121. Issue 11.
Pages 426-430 (January 2003)
Revisiones
Enfermedad pulmonar intersticial
Interstitial lung disease
Visits
3633
Rafael Cuervo
José M. Palau
Corresponding author
rcuervopinto@yahoo.es

Correspondencia: Servicio de Medicina Interna II. Hospital Clínico San Carlos. Martín Lagos, s/n. 28040 Madrid. España.
Servicio de Medicina Interna II. Hospital Clínico Universitario San Carlos. Universidad Complutense. Madrid. España.
This item has received
Article information

El estudio molecular de la fisiopatología de las enfermedades pulmonares intersticiales cobra especial interés en diversos estudios desarrollados en la última década. En dichos estudios parece destacar el papel de varias moléculas, como las citocinas (factor de transformación del crecimiento, factor de crecimiento derivado de plaquetas) y las integrinas en los procesos que llevan al desarrollo de una fibrosis pulmonar durante la evolución de una enfermedad pulmonar intersticial, así como se demuestra el importante papel que desempeña la angiotensina II en la estimulación de la secreción del factor de transformación del crecimiento por diversas células.

Dichos estudios permiten plantear nuevos enfoques terapéuticos que, posiblemente, mejoren el mal pronóstico de estas enfermedades cuando han alcanzado la fase final de su evolución, la fibrosis pulmonar.

Palabras clave:
Fibrosis pulmonar
TGF-β
Integrina alfaVbeta6
Angiotensina II
Enfermedad pulmonar intersticial

Molecular investigation into the physiopathology of interstitial lung diseases has gained special interest through the trials carried out in the last decade. These trials seem to point at the role played by certain molecules, such as cytokines (transforming growth factor, platelet derived growth factor) and integrins, in the processes that lead to pulmonary fibrosis during the course of interstitial lung disease. They also demonstrate the important role that angiotensin II plays in increasing the secretion of transforming growth factor by several cells.

The above-mentioned studies allow new therapeutic approaches to be considered which will possibly improve the serious prognosis of such diseases once they have reached the last stage of their course: pulmonary fibrosis.

Key words:
Pulmonary fibrosis
TGF-β
Integrin alphaVbeta6
Angiotensin II
Interstitial lung disease

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos